🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
Login

News on Medial

Related News

OpenAI expands healthcare push with Color Health’s cancer copilot

LivemintLivemint · 1y ago
OpenAI expands healthcare push with Color Health’s cancer copilot
Medial

OpenAI is collaborating with startup Color Health to implement artificial intelligence (AI) in cancer screening and treatment. Color Health has developed an AI assistant, called a "copilot," using OpenAI's GPT-4o model to aid doctors in creating personalized cancer screening plans and pretreatment plans for patients. The copilot uses patient data and clinical guidelines to generate virtual screening plans and assists in the preparation of pretreatment work-ups. The aim is to alleviate administrative burdens on doctors and improve patient outcomes by reducing delays in treatment. OpenAI's involvement in healthcare is part of its broader expansion strategy beyond its partnership with Microsoft, including recent deals with Apple, PricewaterhouseCoopers, Reddit, and Axel Springer.

Avammune Therapeutics raises $12 Mn in Series A round

EntrackrEntrackr · 2m ago
Avammune Therapeutics raises $12 Mn in Series A round
Medial

Avammune Therapeutics and its subsidiary, Avammune Lifesciences, have secured $12 million in a Series A financing round co-led by Capital 2B, Shastra VC, and Kotak Lifesciences Fund I. The proceeds will be utilized to accelerate its proprietary pipeline, which targets the innate immune system, to develop orally bioavailable small molecules and support the clinical development of lead candidate AVA-NP-695 (an ENPP1 inhibitor). Co-founded in 2020 by Arun B. Papaiah, Srinivasan Namala, and Aditya Kulkarni, Avammune Therapeutics is a biopharmaceutical company discovering small molecule medicines that target the innate immune system for the treatment of cancer and autoimmune disorders. Its pipeline targets Osteosarcoma, Ewing’s Sarcoma, Triple-Negative Breast Cancer, GI cancers, and autoimmune disorders.

Oncare bags $1 Mn in seed round led by Huddle Ventures

EntrackrEntrackr · 9m ago
Oncare bags $1 Mn in seed round led by Huddle Ventures
Medial

Oncare, a cancer care startup, has raised $1 million in its seed round led by Huddle Ventures. The round also saw participation from marquee institutional VCs such as TRTL Ventures, Cloud Capital, and DeVC. The proceeds will be used to expand its operations to 10 new centres across Delhi NCR, Bangalore, and Jaipur over the next two years. The funds will also be channelled towards team expansion and marketing efforts to raise awareness about the brand’s affordable cancer care solutions. Founded in 2023 by Deepak Kumar and Amar Sneh, Oncare is partnering with 50-100 bedded hospitals to create dedicated oncology wings. Through these partnerships, Oncare is reducing treatment costs by up to 40%. The brand claims to offer an affordable yet high-quality alternative to the expensive cancer treatment—often exceeding Rs 10 lakh in corporate hospitals. It also offers on-call nursing support to help patients manage side effects and anxiety associated with cancer therapies, without having to make unnecessary hospital visits. The startup is operational in South Delhi for the past 10 months and it has provided over 2,500 patients with guidance on treatment plans and claims to have completed over 500 treatment sessions. According to the annual Health of Nation report by Apollo Hospitals, the cancer burden in India is staggering, with yearly cases expected to rise from 1.39 million in 2020 to 1.57 million by 2025. However, high treatment costs, limited availability of oncology centres, and a shortage of specialised professionals are making cancer care inaccessible to millions.

Avammune Therapeutics raises $12 Mn in Series A funding round

EntrackrEntrackr · 2m ago
Avammune Therapeutics raises $12 Mn in Series A funding round
Medial

Avammune Therapeutics and its subsidiary, Avammune Lifesciences, have secured $12 million (around Rs 100 crore) in a Series A financing round co-led by Capital 2B, Shastra VC, and Kotak Lifesciences Fund I, a fund managed by Kotak Alternate Asset Managers, with participation from IvyCap Ventures alongside existing investor 1Crowd. The proceeds will be utilized to accelerate its proprietary pipeline, which targets the innate immune system, to develop orally bioavailable small molecules and support the clinical development of lead candidate AVA-NP-695 (an ENPP1 inhibitor), Avammune Therapeutics said in a press release. Co-founded in 2020 by Arun B. Papaiah, Srinivasan Namala, and Aditya Kulkarni, Avammune Therapeutics is a biopharmaceutical company discovering small molecule medicines that target the innate immune system for the treatment of cancer and autoimmune disorders. Its pipeline targets Osteosarcoma, Ewing’s Sarcoma, Triple-Negative Breast Cancer, GI cancers, and autoimmune disorders. According to Avammune, its lead asset is an ENPP1 inhibitor that has demonstrated strong anti-tumor efficacy in several preclinical models of cancer and also in veterinary cancer patients in “compassionate use” settings. AVA-ADR is a potential first-in-class ADAR1 p150 inhibitor and one of the only ADAR1 inhibitors in the landscape to demonstrate in vivo efficacy. According to market research, the global immuno-oncology market is about $100 billion and is rapidly growing at a CAGR of 17%.

OneCell Diagnostics raises $16 million in round led by Celesta Capital, others

Economic TimesEconomic Times · 7m ago
OneCell Diagnostics raises $16 million in round led by Celesta Capital, others
Medial

OneCell Diagnostics, a startup specializing in AI-powered cancer diagnostics, has raised $16 million in a series A funding round. The funding was led by Celesta Capital and included participation from Tenacity Ventures, Cedars Sinai, Eragon, and Singularity Ventures. OneCell plans to use the funds to expand to the US market with its liquid biopsy test, OncoIndx Alfa, which detects circulating tumor cells for precision diagnosis and treatment of cancer. The funding will also help the company democratize precision oncology by making cancer diagnostic testing more accessible and affordable. OneCell has already tested its technology in India and has partnerships with leading medical institutions.

Download the medial app to read full posts, comements and news.